# Grace Therapeutics, Inc.

**GRCE**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001444192

# None

### No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $66.7M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | thin data, degenerate inputs<br>not computable: distress, fortress balance sheet |
| **Inputs computable** | 5 of 14 |
| **Graded from** | filings received through Jun 18, 2026<br>130 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026 |
| **Last close** | $1.92<br>2026-10-23; market equity $40.4M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Jun 18, 2026*

We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients used in the drug candidates under development by us may be already approved in a target indication or could be repurposed for use in new indications.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 83.0** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |

*latest aligned inputs end 2022-03-31; latest annual assets end 2026-03-31*

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | 1.6% | (6.6%) | | 83.0 | 807 | 2026-03-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 2* | | | | | | |
| **Solvency, sleeve percentile 14.0** | | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | | |
| *four consecutive discrete net-income quarters are required; found 4* | | | | | | |
| Altman Z double-prime | 13.53 | (0.33) | | 6.0 | 752 | 2026-03-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 8.10x | 2.94x | | 22.0 | 834 | 2026-03-31 |
| **Growth and financing, sleeve percentile 60.2** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *four annual observations are required; found 2* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *four consecutive annual FCF observations are required; found 0* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Asset growth, three years | (5.6%) | 2.1% | | 62.8 | 700 | 2026-03-31 |
| Net share issuance, one year | 17.7% | 2.5% | | 57.6 | 636 | 2026-06-15 |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 5 of 14 grade factors are computable; minimum is 7 |
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |

## What the price implies

*at the 2026-10-23 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (28.5%) | 7.7% | 26 |
| Distance from 52-week high | (62.4%) | (31.4%) | 19 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | not computable | (1.0%) | |
| Book value to price | 1.19 | 0.28 | 89 |
| Sales to price | 0.00 | 0.30 | 0 |
| Composite equity issuance, five years | 157.8% | 20.5% | 86 |
| Relative strength against the sector, log excess return | (0.55) | (0.14) | 26 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2026-03-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $13.8M |
| Operating cash flow, four quarters | -$10.3M |
| Months of runway | 16.0 |
| Days since last periodic filing | 74 (10-Q received Aug 13, 2026) |
| Median daily dollar volume, 63 sessions | $213,135 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerIncludingAs... | $0 | 2022-03-31 | 2022-06-21 | 10-K | 22-011842 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $0 | 2022-03-31 | 2022-06-21 | 10-K | 22-011842 |
| 3 | assets | us-gaap:Assets | $128.6M | 2022-03-31 | 2023-06-23 | 10-K | 23-029498 |
| 4 | net income | us-gaap:NetIncomeLoss | -$7.8M | 2026-03-31 | 2026-06-18 | 10-K | 26-025662 |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$8.9M | 2026-03-31 | 2026-06-18 | 10-K | 26-025662 |
| 6 | assets | us-gaap:Assets | $66.7M | 2026-03-31 | 2026-06-18 | 10-K | 26-025662 |
| 7 | assets | us-gaap:Assets | $72.0M | 2025-03-31 | 2026-06-18 | 10-K | 26-025662 |
| 8 | current assets | us-gaap:AssetsCurrent | $17.4M | 2026-03-31 | 2026-06-18 | 10-K | 26-025662 |
| 9 | current liabilities | us-gaap:LiabilitiesCurrent | $2.1M | 2026-03-31 | 2026-06-18 | 10-K | 26-025662 |
| 10 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$228.5M | 2026-03-31 | 2026-06-18 | 10-K | 26-025662 |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$11.1M | 2026-03-31 | 2026-06-18 | 10-K | 26-025662 |
| 12 | book equity | us-gaap:StockholdersEquity | $63.9M | 2026-03-31 | 2026-06-18 | 10-K | 26-025662 |
| 13 | liabilities | us-gaap:Liabilities | $2.8M | 2026-03-31 | 2026-06-18 | 10-K | 26-025662 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerIncludingAs... | $196,000 | 2021-03-31 | 2022-06-21 | 10-K | 22-011842 |
| 15 | assets | us-gaap:Assets | $73.3M | 2024-03-31 | 2025-06-23 | 10-K | 25-023259 |
| 16 | assets | us-gaap:Assets | $79.1M | 2023-03-31 | 2024-06-21 | 10-K | 24-075875 |
| 17 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 16,274,026 | 2026-06-15 | 2026-06-18 | 10-K | 26-025662 |
| 18 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 13,828,562 | 2025-06-19 | 2025-06-23 | 10-K | 25-023259 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.